Positive News SentimentPositive NewsNASDAQ:CLLS Cellectis (CLLS) Stock Price, News & Analysis $2.67 +0.08 (+3.09%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$2.70 +0.04 (+1.31%) As of 08/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cellectis Stock (NASDAQ:CLLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cellectis alerts:Sign Up Key Stats Today's Range$2.59▼$2.7450-Day Range$1.38▼$3.0252-Week Range$1.10▼$3.24Volume25,763 shsAverage Volume142,522 shsMarket Capitalization$148.40 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Read More Cellectis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreCLLS MarketRank™: Cellectis scored higher than 70% of companies evaluated by MarketBeat, and ranked 304th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectis has received no research coverage in the past 90 days.Read more about Cellectis' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cellectis are expected to decrease in the coming year, from ($0.46) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cellectis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.38% of the float of Cellectis has been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectis has recently decreased by 32.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.38% of the float of Cellectis has been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectis has recently decreased by 32.04%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment1.88 News SentimentCellectis has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cellectis this week, compared to 1 article on an average week.Search Interest7 people have searched for CLLS on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cellectis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by Insiders16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cellectis' insider trading history. Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLLS Stock News HeadlinesCellectis S.A. Earnings Call: Progress Amid ChallengesAugust 10, 2025 | theglobeandmail.comCellectis S.A. Reports Interim Financial Results for First Half of 2025August 6, 2025 | theglobeandmail.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. | Banyan Hill Publishing (Ad)Earnings To Watch: Cellectis SA (CLLS) Reports Q2 2025 ResultAugust 6, 2025 | finance.yahoo.comCellectis S.A. (CLLS) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comCellectis Reports Second Quarter 2025 Financial Results & Business UpdatesAugust 4, 2025 | globenewswire.comCellectis to Announce Q2 2025 Financial Results on August 4July 30, 2025 | theglobeandmail.comCellectis to Report Second Quarter 2025 Financial Results on August 4, 2025July 28, 2025 | globenewswire.comSee More Headlines CLLS Stock Analysis - Frequently Asked Questions How have CLLS shares performed this year? Cellectis' stock was trading at $1.80 at the start of the year. Since then, CLLS stock has increased by 48.3% and is now trading at $2.67. How were Cellectis' earnings last quarter? Cellectis S.A. (NASDAQ:CLLS) released its earnings results on Monday, August, 4th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.09. The biotechnology company had revenue of $18.19 million for the quarter, compared to analyst estimates of $10.07 million. Cellectis had a negative trailing twelve-month return on equity of 68.05% and a negative net margin of 100.69%. Read the conference call transcript. When did Cellectis IPO? Cellectis (CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager. How do I buy shares of Cellectis? Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA). Company Calendar Last Earnings8/04/2025Today8/27/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLLS CIK1627281 Webwww.cellectis.com Phone(318) 169-1600Fax33-1-81-69-16-06Employees290Year FoundedN/APrice Target and Rating Average Price Target for Cellectis$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+51.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.76 million Net Margins-100.69% Pretax Margin-71.84% Return on Equity-68.05% Return on Assets-21.53% Debt Debt-to-Equity Ratio0.58 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$49.22 million Price / Sales2.99 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book1.51Miscellaneous Outstanding Shares55,580,000Free Float46,463,000Market Cap$147.01 million OptionableOptionable Beta3.03 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:CLLS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBreaking News: Trump Could Unlock $21 Trillion for Everyday AmericansPresident Trump just signed a new law… That could unlock $21 trillion for everyday folks like you… And p...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredMusk's Big Prediction for 2025Elon Musk just made a bold prediction about 2025—and it could upend the entire tech sector. If he’s right, ...The Oxford Club | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.